JO3026B1 - مستضادات ببتيد شبيه الجلوكاجون - 2 - Google Patents
مستضادات ببتيد شبيه الجلوكاجون - 2Info
- Publication number
- JO3026B1 JO3026B1 JOP/2010/0352A JOP20100352A JO3026B1 JO 3026 B1 JO3026 B1 JO 3026B1 JO P20100352 A JOP20100352 A JO P20100352A JO 3026 B1 JO3026 B1 JO 3026B1
- Authority
- JO
- Jordan
- Prior art keywords
- agonists
- glp
- peptidic glp
- peptidic
- analogs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Nutrition Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
Abstract
يتعلق الاختراع الحالي بنظائر GLP-2 جديدة ذات خصائص حركة دوائية محسنة فضلا عن استخدامها في علاج الأمراض.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25449009P | 2009-10-23 | 2009-10-23 | |
EP09173900A EP2314616A1 (en) | 2009-10-23 | 2009-10-23 | Peptidic GLP-2 agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
JO3026B1 true JO3026B1 (ar) | 2016-09-05 |
Family
ID=41572524
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2010/0352A JO3026B1 (ar) | 2009-10-23 | 2010-10-14 | مستضادات ببتيد شبيه الجلوكاجون - 2 |
Country Status (19)
Country | Link |
---|---|
US (1) | US8580918B2 (ar) |
EP (2) | EP2314616A1 (ar) |
JP (1) | JP5755653B2 (ar) |
KR (1) | KR101794781B1 (ar) |
CN (1) | CN102711802B (ar) |
AR (1) | AR079877A1 (ar) |
AU (1) | AU2010310665B2 (ar) |
CA (1) | CA2777758C (ar) |
DK (1) | DK2490709T3 (ar) |
ES (1) | ES2530615T3 (ar) |
JO (1) | JO3026B1 (ar) |
NZ (1) | NZ599137A (ar) |
PL (1) | PL2490709T3 (ar) |
PT (1) | PT2490709E (ar) |
RS (1) | RS53882B1 (ar) |
RU (1) | RU2551977C2 (ar) |
SI (1) | SI2490709T1 (ar) |
TW (1) | TWI482627B (ar) |
WO (1) | WO2011050174A1 (ar) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
WO2015160703A1 (en) * | 2014-04-14 | 2015-10-22 | Nps Pharmaceuticals, Inc. | Treatment methods for gut-mediated hiv immune dysfunction |
US20160067311A1 (en) * | 2014-09-10 | 2016-03-10 | Helsinn Healthcare Sa | Use of elsiglutide to treat gastrointestinal mucositis including chemotherapy-induced diarrhea |
US9783766B2 (en) | 2015-04-03 | 2017-10-10 | Ecolab Usa Inc. | Enhanced peroxygen stability using anionic surfactant in TAED-containing peroxygen solid |
CA3030533A1 (en) | 2016-07-11 | 2018-01-18 | Oren HERSHKOVITZ | Long-acting coagulation factor vii and methods of producing same |
WO2019086559A1 (fr) | 2017-10-31 | 2019-05-09 | Adocia | Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes |
US20200254065A1 (en) * | 2019-02-11 | 2020-08-13 | Opko Biologics Ltd. | Long-acting glp-2 analogs |
BR112022006546A2 (pt) | 2019-10-07 | 2022-08-30 | Kallyope Inc | Agonistas de gpr119 |
IL296464A (en) * | 2020-03-16 | 2022-11-01 | Heptares Therapeutics Ltd | Oral glp receptor agonists |
GB202003762D0 (en) * | 2020-03-16 | 2020-04-29 | Heptares Therapeutics Ltd | GLP receptor agonists |
EP4126004A1 (en) | 2020-03-30 | 2023-02-08 | Zealand Pharma A/S | Agonist combination |
JP2023526625A (ja) | 2020-05-19 | 2023-06-22 | キャリーオペ,インク. | Ampkアクチベーター |
CN111560061A (zh) * | 2020-05-26 | 2020-08-21 | 成都圣诺生物制药有限公司 | 一种Gelpaglutide的制备方法 |
KR20230038187A (ko) * | 2020-06-09 | 2023-03-17 | 벡티브바이오 에이지 | 아프라글루타이드의 제조, 제형화 및 투여 |
CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
CA3206093A1 (en) * | 2021-01-28 | 2022-08-04 | Violetta Dimitriadou | Compositions and methods for the treatment of graft versus host disease |
CN116751278B (zh) * | 2023-06-21 | 2024-02-13 | 杭州信海医药科技有限公司 | 一种Glepaglutide的制备方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5834428A (en) | 1995-04-14 | 1998-11-10 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
US5990077A (en) | 1995-04-14 | 1999-11-23 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
US6184201B1 (en) * | 1995-04-14 | 2001-02-06 | Nps Allelix Corp. | Intestinotrophic glucagon-like peptide-2 analogs |
EP2218734B1 (en) * | 1996-04-12 | 2013-06-05 | 1149336 Ontario Inc. | Glucagon-like peptide-2 analogs |
US5994500A (en) * | 1996-07-19 | 1999-11-30 | 1149336 Ontario Inc. | Antagonists of intestinotrophic GLP-2 peptides |
GB9930882D0 (en) | 1999-12-30 | 2000-02-23 | Nps Allelix Corp | GLP-2 formulations |
JP4280070B2 (ja) * | 2001-02-16 | 2009-06-17 | コンジュケム バイオテクノロジーズ インコーポレイテッド | 胃腸疾患および胃腸障害の処置のための長期持続性グルカゴン様ペプチド2(glp−2) |
RU2005114512A (ru) * | 2002-10-14 | 2006-12-27 | Ново Нордиск А/С (DK) | Варианты глюкагон-подобного пептида-2 |
ATE498631T1 (de) | 2005-05-04 | 2011-03-15 | Zealand Pharma As | Glucagon-like-peptide-2- (glp-2-) analoga |
US8642727B2 (en) * | 2006-11-08 | 2014-02-04 | Zealand Pharma A/S | Selective glucagon-like-peptide-2 (GLP-2) analogues |
-
2009
- 2009-10-23 EP EP09173900A patent/EP2314616A1/en not_active Withdrawn
-
2010
- 2010-10-14 JO JOP/2010/0352A patent/JO3026B1/ar active
- 2010-10-20 TW TW099135726A patent/TWI482627B/zh active
- 2010-10-21 PT PT10825678T patent/PT2490709E/pt unknown
- 2010-10-21 US US13/503,010 patent/US8580918B2/en active Active
- 2010-10-21 ES ES10825678T patent/ES2530615T3/es active Active
- 2010-10-21 KR KR1020127010424A patent/KR101794781B1/ko active IP Right Grant
- 2010-10-21 SI SI201030857T patent/SI2490709T1/sl unknown
- 2010-10-21 NZ NZ599137A patent/NZ599137A/xx unknown
- 2010-10-21 CA CA2777758A patent/CA2777758C/en active Active
- 2010-10-21 WO PCT/US2010/053570 patent/WO2011050174A1/en active Application Filing
- 2010-10-21 AU AU2010310665A patent/AU2010310665B2/en active Active
- 2010-10-21 PL PL10825678T patent/PL2490709T3/pl unknown
- 2010-10-21 RS RS20150116A patent/RS53882B1/en unknown
- 2010-10-21 RU RU2012116046/10A patent/RU2551977C2/ru active
- 2010-10-21 EP EP10825678.5A patent/EP2490709B1/en active Active
- 2010-10-21 DK DK10825678.5T patent/DK2490709T3/da active
- 2010-10-21 JP JP2012535371A patent/JP5755653B2/ja active Active
- 2010-10-21 CN CN201080047813.6A patent/CN102711802B/zh active Active
- 2010-10-22 AR ARP100103897A patent/AR079877A1/es active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
US8580918B2 (en) | 2013-11-12 |
TW201119668A (en) | 2011-06-16 |
AR079877A1 (es) | 2012-02-29 |
KR101794781B1 (ko) | 2017-11-09 |
SI2490709T1 (sl) | 2015-04-30 |
PT2490709E (pt) | 2015-03-04 |
EP2490709B1 (en) | 2014-11-26 |
CN102711802A (zh) | 2012-10-03 |
JP2013508398A (ja) | 2013-03-07 |
TWI482627B (zh) | 2015-05-01 |
KR20120100942A (ko) | 2012-09-12 |
JP5755653B2 (ja) | 2015-07-29 |
NZ599137A (en) | 2013-04-26 |
EP2490709A1 (en) | 2012-08-29 |
AU2010310665A1 (en) | 2012-05-03 |
WO2011050174A1 (en) | 2011-04-28 |
EP2314616A1 (en) | 2011-04-27 |
PL2490709T3 (pl) | 2015-04-30 |
CN102711802B (zh) | 2017-03-22 |
EP2490709A4 (en) | 2013-05-15 |
AU2010310665B2 (en) | 2014-10-23 |
CA2777758C (en) | 2018-06-05 |
RS53882B1 (en) | 2015-08-31 |
RU2551977C2 (ru) | 2015-06-10 |
ES2530615T3 (es) | 2015-03-04 |
CA2777758A1 (en) | 2011-04-28 |
DK2490709T3 (da) | 2015-01-05 |
RU2012116046A (ru) | 2013-11-27 |
US20120231999A1 (en) | 2012-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JO3026B1 (ar) | مستضادات ببتيد شبيه الجلوكاجون - 2 | |
MX2012013375A (es) | Peptido c pegilado. | |
IN2012DN02737A (ar) | ||
EA201270619A1 (ru) | Применение бетанехола для лечения ксеростомии | |
CL2013000018A1 (es) | Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros. | |
MX2019000225A (es) | Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades. | |
MX2011007930A (es) | Conjugados de insulina cristalina. | |
UA102432C2 (ru) | Цитотоксичные конъюгаты с соединением, которое связывает рецептор нейропептиду y | |
IT1395519B1 (it) | Pezzo composito, nonche' impiego del pezzo composito | |
CL2011001427A1 (es) | Compuestos derivados de 4-azetidinil-1-heteroaril-ciclohexanol; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como epoc, aterosclerosis, artritis reumatoide, entre otras. | |
CL2009001006A1 (es) | Compuestos derivados del acido 4-dimetil-aminobutirico; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de enfermedades tales como hiperglucemia, diabetes e hipertension entre otras. | |
MX2012004727A (es) | Agonistas peptidicos del glp-2. | |
IN2012DN03074A (ar) | ||
MX2012012509A (es) | Tapentadol para usarse en el tratamiento del sindrome del intestino irritable. | |
PA8849101A1 (es) | Procedimiento de preparación del hemifumarato de eplivanserina | |
CY1116095T1 (el) | Πεπτιδικοι αγωνιστες gla-2 | |
UA41660U (en) | Use of jacton and mexidol as actoprotector | |
UA92646C2 (ru) | применение производных 2-оксоиндолин-3-глиоксиловой кислоты в качестве средств с актопротекторным действием | |
UA35660U (en) | Use of antihomotoxic preparations as cytoprotectors | |
TH114350B (th) | เก้าอี้ | |
UA52376U (ru) | Применение КОРВИТИНА в качестве средства фригопротекторного действия | |
UA52378U (ru) | Применение ЛИПОФЛАВОНА в качестве средства фригопротекторного действия | |
UA52379U (ru) | Применение ЛИПИНА в качестве средства фригопротекторного действия | |
TR200900104U (tr) | Çocuk muayene masası. | |
TH108693B (th) | เตียง |